Trial · NCT03580343
Tofacitinib for Inflammatory Eye Disease
NCT03580343, Phase 2, Unknown, Washington University School of Medicine; results first posted 2021-02-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tofacitinib for Inflammatory Eye Disease. Trials, record NCT03580343. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03580343
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tofacitinib for Inflammatory Eye Disease
- NCT number
- NCT03580343
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Uveitis, Scleritis
- Interventions
- tofacitinib
- First posted
- 2018-07-09
- Last updated
- 2021-02-01
- Results first posted
- 2021-02-01
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment Failure (Composite Outcome) | 180 days | new inflammatory lesions relative to baseline OR 2-step increase in anterior chamber cell or vitreous haze OR worsening of visual acuity by two or more rows on ETDRS chart |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Treatment Failure (Composite Outcome) | 180 days | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Treatment Failure (Composite Outcome) | Tofacitinib Treatment | 0 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tofacitinib Treatment | 5 | |
| Overall Study | COMPLETED | Tofacitinib Treatment | 4 | |
| Overall Study | NOT COMPLETED | Tofacitinib Treatment | 1 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | cutaneous melanoma | Skin and subcutaneous tissue disorders | Tofacitinib Treatment | 1 | 5 | 1 |
| serious | squamous cell carcinoma | Skin and subcutaneous tissue disorders | Tofacitinib Treatment | 1 | 5 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tofacitinib Treatment | 0 | 5 |
| Total, other adverse events | Tofacitinib Treatment | 0 | 5 |
| Total, serious adverse events | Tofacitinib Treatment | 2 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03580343
GET https://conductscience.org/api/trials/v1/NCT03580343/registered